WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Mazdutide

Governed registry record

28 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    DOI: 10.12688/f1000research.186847.1

    Source identity and connection checked by Codex (AI).

  2. Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    DOI: 10.12688/f1000research.186694.1

    Source identity and connection checked by Codex (AI).

  3. Efficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis

    DOI: 10.21203/rs.3.rs-9477385/v1

    Source identity and connection checked by Codex (AI).

  4. Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis

    DOI: 10.21203/rs.3.rs-7884657/v1

    Source identity and connection checked by Codex (AI).

  5. Mazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum Stress

    DOI: 10.20944/preprints202601.1103.v1

    Source identity and connection checked by Codex (AI).

  6. Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

    2026

    DOI: 10.1111/dom.70643PMID: 41804840

  7. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

    2026

    DOI: 10.1111/dom.71058PMID: 42410325

  8. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

    2026

    DOI: 10.1016/s2213-8587(26)00160-9PMID: 42628555

  9. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.

    2026

    DOI: 10.1016/j.medj.2026.101063PMID: 41875890

  10. Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.

    2026

    DOI: 10.3390/ph19030371PMID: 41901218

  11. Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.

    2026

    DOI: 10.1001/jama.2026.10443PMID: 42251768

  12. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.

    2026

    DOI: 10.1016/j.cct.2025.108150PMID: 41260459

  13. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

    2026

    DOI: 10.1038/s41586-025-10031-zPMID: 41407860

  14. Mazdutide versus placebo in Chinese adults with type 2 diabetes.

    2026

    DOI: 10.1038/s41586-025-10026-wPMID: 41407859

  15. Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.

    2026

    DOI: 10.1080/13543776.2026.2645812PMID: 41820018

  16. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.

    2026

    DOI: 10.1001/jama.2026.8427PMID: 42251596

  17. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

    2026

    DOI: 10.1001/jama.2026.8142PMID: 42251595

  18. Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.

    2025

    DOI: 10.3389/fendo.2025.1654506PMID: 41030857

  19. Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

    2025

    DOI: 10.1111/dom.70040PMID: 40832785

  20. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.

    2025

    DOI: 10.1016/j.ebiom.2025.105791PMID: 40479843

  21. Mazdutide: First Approval.

    2025

    DOI: 10.1007/s40265-025-02249-yPMID: 41028652

  22. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

    2025

    DOI: 10.1056/nejmoa2411528PMID: 40421736

  23. Once-Weekly Mazdutide in Obesity or Overweight. Reply.

    2025

    DOI: 10.1056/nejmc2509841PMID: 40929642

  24. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

    2024

    DOI: 10.2337/dc23-1287PMID: 37943529

  25. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

    2024

    DOI: 10.3389/fendo.2024.1309118PMID: 38440786

  26. Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.

    2024

    DOI: 10.1097/mjt.0000000000001756PMID: 39292847

  27. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

    2023

    DOI: 10.1038/s41467-023-44067-4PMID: 38092790

  28. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

    2022

    DOI: 10.1016/j.eclinm.2022.101691PMID: 36247927